{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:56:29Z","timestamp":1784289389582,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HRAS is a ubiquitously expressed protein and functions as a central regulator of cellular homeostasis. In somatic cells, mutations in this gene cause cancer, while germline mutations trigger a developmental disorder known as Costello syndrome (CS). Among numerous pathologies, adult CS patients develop osteoporosis. Previous studies revealed that HRAS is implicated in bone homeostasis by controlling osteoblast differentiation, adaptation to mechanical strain and repression of RANKL expression in mature osteoblasts, and by regulating osteoclast differentiation. However, the impact of HRAS on osteoblast differentiation is still debatable. In this study, we created stable doxycycline inducible cell lines overexpressing HRAS G12 mutants in MC3T3-E1 preosteoblast cell line and analyzed their impact on osteoblast differentiation. We demonstrated an inhibitory role of HRAS G12S and HRAS G12V mutants on osteogenic differentiation and identified an increased expression of Opn in an HRAS-dependent manner, which directly correlated with impaired osteogenesis, and was rescued by the farnesyl transferase inhibitor Tipifarnib. At the molecular level, Tipifarnib was not able to block HRAS activation, but impaired HRAS localization to the plasma membrane, and inhibited MAPK activation and Opn expression. Thus, HRAS abundance\/activation and its potential crosstalk with OPN may be more critical for osteogenic differentiation than previously assumed.<\/jats:p>","DOI":"10.1038\/s41598-025-91592-x","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T19:28:41Z","timestamp":1740511721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib"],"prefix":"10.1038","volume":"15","author":[{"given":"Yannik","family":"Andrasch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses Munene","family":"Ireri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Gander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Engelke Sabrina","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravanakkumar","family":"Chennappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miray","family":"Fidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Engler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion Cristian","family":"Cirstea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"33","key":"91592_CR1","doi-asserted-by":"publisher","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","volume":"285","author":"LJ Raggatt","year":"2010","unstructured":"Raggatt, L. J. & Partridge, N. C. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103\u201325108. https:\/\/doi.org\/10.1074\/jbc.R109.041087 (2010).","journal-title":"J. Biol. Chem."},{"key":"91592_CR2","doi-asserted-by":"publisher","unstructured":"Kim, J. M., Lin, C., Stavre, Z., Greenblatt, M. B. & Shim, J. H. Osteoblast-osteoclast communication and bone homeostasis. Cells 9(9), 2073. https:\/\/doi.org\/10.3390\/cells9092073 (2020).","DOI":"10.3390\/cells9092073"},{"issue":"2","key":"91592_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7150\/ijbs.2929","volume":"8","author":"G Chen","year":"2012","unstructured":"Chen, G., Deng, C. & Li, Y. P. TGF-\u03b2 and BMP signaling in osteoblast differentiation and bone formation. Int. J. Biol. Sci. 8(2), 272\u2013288. https:\/\/doi.org\/10.7150\/ijbs.2929 (2012).","journal-title":"Int. J. Biol. Sci."},{"key":"91592_CR4","doi-asserted-by":"publisher","unstructured":"Huang, W. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front. Biosci. https:\/\/doi.org\/10.2741\/2296 (2007).","DOI":"10.2741\/2296"},{"key":"91592_CR5","doi-asserted-by":"publisher","unstructured":"Florencio-Silva, R., da Sasso, G. R., Sasso-Cerri, E., Sim\u00f5es, M. J. & Cerri, P. S. Biology of bone tissue: Structure, function, and factors that influence bone cells. Biomed. Res. Int. 1\u201317. https:\/\/doi.org\/10.1155\/2015\/421746 (2015).","DOI":"10.1155\/2015\/421746"},{"key":"91592_CR6","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/TCRM.S138000","volume":"14","author":"F Pouresmaeili","year":"2018","unstructured":"Pouresmaeili, F., Kamali Dehghan, B., Kamarehei, M. & Yong Meng, G. A comprehensive overview on osteoporosis and its risk factors. Ther. Clin. Risk Manag. 14, 2029\u20132049. https:\/\/doi.org\/10.2147\/TCRM.S138000 (2018).","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"91592_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymgme.2012.04.003","volume":"106","author":"KS Choudhry","year":"2012","unstructured":"Choudhry, K. S. et al. Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway? Mol. Genet. Metab. 106(2), 237\u2013240. https:\/\/doi.org\/10.1016\/j.ymgme.2012.04.003 (2012).","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"91592_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ajmg.a.30747","volume":"136A","author":"SM White","year":"2005","unstructured":"White, S. M. et al. The adult phenotype in Costello syndrome. Am. J. Med. Genet. A 136A(2), 128\u2013135. https:\/\/doi.org\/10.1002\/ajmg.a.30747 (2005).","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"91592_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","volume":"14","author":"KA Rauen","year":"2013","unstructured":"Rauen, K. A. The RASopathies. Annu. Rev. Genomics Hum. Genet. 14(1), 355\u2013369. https:\/\/doi.org\/10.1146\/annurev-genom-091212-153523 (2013).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"7","key":"91592_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","volume":"9","author":"AE Karnoub","year":"2008","unstructured":"Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: Split personalities. Nat. Rev. Mol. Cell. Biol. 9(7), 517\u2013531. https:\/\/doi.org\/10.1038\/nrm2438 (2008).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"10","key":"91592_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/ng1641","volume":"37","author":"Y Aoki","year":"2005","unstructured":"Aoki, Y. et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet. 37(10), 1038\u20131040. https:\/\/doi.org\/10.1038\/ng1641 (2005).","journal-title":"Nat. Genet."},{"issue":"9","key":"91592_CR12","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/ajmg.a.34150","volume":"155","author":"KW Gripp","year":"2011","unstructured":"Gripp, K. W. et al. Molecular confirmation of HRAS p.G12S in siblings with Costello syndrome. Am. J. Med. Genet. A 155(9), 2263\u20132268. https:\/\/doi.org\/10.1002\/ajmg.a.34150 (2011).","journal-title":"Am. J. Med. Genet. A"},{"key":"91592_CR13","doi-asserted-by":"publisher","unstructured":"Kerr, B. et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J. Med. Genet. 43(5), 401\u2013405. https:\/\/doi.org\/10.1136\/jmg.2005.040352 (2006).","DOI":"10.1136\/jmg.2005.040352"},{"issue":"5","key":"91592_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/ajmg.a.35296","volume":"158A","author":"EMM Burkitt-Wright","year":"2012","unstructured":"Burkitt-Wright, E. M. M. et al. Neonatal lethal Costello syndrome and unusual dinucleotide deletion\/insertion mutations in HRAS predicting p.Gly12Val. Am. J. Med. Genet. A 158A(5), 1102\u20131110. https:\/\/doi.org\/10.1002\/ajmg.a.35296 (2012).","journal-title":"Am. J. Med. Genet. A"},{"issue":"47","key":"91592_CR15","doi-asserted-by":"publisher","first-page":"8465","DOI":"10.1021\/bi400679q","volume":"52","author":"M Wey","year":"2013","unstructured":"Wey, M., Lee, J., Jeong, S. S., Kim, J. & Heo, J. Kinetic mechanisms of Mutation-Dependent Harvey Ras activation and their relevance for the development of Costello syndrome. Biochemistry 52(47), 8465\u20138479. https:\/\/doi.org\/10.1021\/bi400679q (2013).","journal-title":"Biochemistry"},{"issue":"15","key":"91592_CR16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.4161\/cc.5.15.3128","volume":"5","author":"CP Kratz","year":"2006","unstructured":"Kratz, C. P. et al. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell. Cycle 5(15), 1607\u20131611. https:\/\/doi.org\/10.4161\/cc.5.15.3128 (2006).","journal-title":"Cell. Cycle"},{"issue":"3","key":"91592_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ng1748","volume":"38","author":"S Schubbert","year":"2006","unstructured":"Schubbert, S. et al. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38(3), 331\u2013336. https:\/\/doi.org\/10.1038\/ng1748 (2006).","journal-title":"Nat. Genet."},{"issue":"7","key":"91592_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/jcb.24779","volume":"115","author":"NS Adapala","year":"2014","unstructured":"Adapala, N. S., Barbe, M. F., Tsygankov, A. Y., Lorenzo, J. A. & Sanjay, A. Loss of Cbl\u2013PI3K interaction enhances osteoclast survival due to p21-Ras mediated PI3K activation independent of Cbl\u2010b. J. Cell. Biochem. 115(7), 1277\u20131289. https:\/\/doi.org\/10.1002\/jcb.24779 (2014).","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"91592_CR19","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1074\/jbc.M606706200","volume":"282","author":"N Ghosh-Choudhury","year":"2007","unstructured":"Ghosh-Choudhury, N., Mandal, C. C. & Choudhury, G. G. Statin-induced Ras activation integrates the phosphatidylinositol 3-Kinase signal to Akt and MAPK for bone morphogenetic Protein-2 expression in osteoblast differentiation. J. Biol. Chem. 282(7), 4983\u20134993. https:\/\/doi.org\/10.1074\/jbc.M606706200 (2007).","journal-title":"J. Biol. Chem."},{"key":"91592_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78069","author":"JM Kim","year":"2022","unstructured":"Kim, J. M. et al. Biphasic regulation of osteoblast development via the ERK MAPK\u2013mTOR pathway. Elife. https:\/\/doi.org\/10.7554\/eLife.78069 (2022).","journal-title":"Elife"},{"issue":"21","key":"91592_CR21","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1128\/MCB.01549-08","volume":"29","author":"T Matsushita","year":"2009","unstructured":"Matsushita, T. et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell. Biol. 29(21), 5843\u20135857. https:\/\/doi.org\/10.1128\/MCB.01549-08 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"91592_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1000575","author":"S Nandi","year":"2022","unstructured":"Nandi, S. et al. Increased osteoclastogenesis contributes to bone loss in the Costello syndrome Hras G12V mouse model. Front. Cell. Dev. Biol.https:\/\/doi.org\/10.3389\/fcell.2022.1000575 (2022).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"11","key":"91592_CR23","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1172\/JCI29092","volume":"116","author":"FC Yang","year":"2006","unstructured":"Yang, F. C. et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1\u2013haploinsufficient osteoclast functions. J. Clin. Invest. 116(11), 2880\u20132891. https:\/\/doi.org\/10.1172\/JCI29092 (2006).","journal-title":"J. Clin. Invest."},{"issue":"47","key":"91592_CR24","doi-asserted-by":"publisher","first-page":"32533","DOI":"10.1074\/jbc.M109.040980","volume":"284","author":"C Ge","year":"2009","unstructured":"Ge, C. et al. Identification and functional characterization of ERK\/MAPK phosphorylation sites in the Runx2 transcription factor. J. Biol. Chem. 284(47), 32533\u201332543. https:\/\/doi.org\/10.1074\/jbc.M109.040980 (2009).","journal-title":"J. Biol. Chem."},{"issue":"10","key":"91592_CR25","doi-asserted-by":"publisher","first-page":"e2405","DOI":"10.1038\/cddis.2016.314","volume":"7","author":"G Papaioannou","year":"2016","unstructured":"Papaioannou, G., Mirzamohammadi, F. & Kobayashi, T. Ras signaling regulates osteoprogenitor cell proliferation and bone formation. Cell. Death Dis. 7(10), e2405\u2013e2405. https:\/\/doi.org\/10.1038\/cddis.2016.314 (2016).","journal-title":"Cell. Death Dis."},{"issue":"6","key":"91592_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cmet.2006.10.010","volume":"4","author":"F Elefteriou","year":"2006","unstructured":"Elefteriou, F. et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell. Metab. 4(6), 441\u2013451. https:\/\/doi.org\/10.1016\/j.cmet.2006.10.010 (2006).","journal-title":"Cell. Metab."},{"issue":"3","key":"91592_CR27","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1074\/jbc.M508639200","volume":"281","author":"J Rubin","year":"2006","unstructured":"Rubin, J. et al. Mechanical Inhibition of RANKL expression is regulated by H-Ras-GTPase. J. Biol. Chem. 281(3), 1412\u20131418. https:\/\/doi.org\/10.1074\/jbc.M508639200 (2006).","journal-title":"J. Biol. Chem."},{"issue":"8","key":"91592_CR28","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.stemcr.2021.06.007","volume":"16","author":"JB Choi","year":"2021","unstructured":"Choi, J. B. et al. Dysregulated ECM remodeling proteins lead to aberrant osteogenesis of Costello syndrome iPSCs. Stem Cell. Rep. 16(8), 1985\u20131998. https:\/\/doi.org\/10.1016\/j.stemcr.2021.06.007 (2021).","journal-title":"Stem Cell. Rep."},{"issue":"24","key":"91592_CR29","doi-asserted-by":"publisher","first-page":"21446","DOI":"10.1074\/jbc.M202238200","volume":"277","author":"Y Tanaka","year":"2002","unstructured":"Tanaka, Y. et al. H-Ras\/Mitogen-activated protein kinase pathway inhibits Integrin-mediated adhesion and induces apoptosis in osteoblasts. J. Biol. Chem. 277(24), 21446\u201321452. https:\/\/doi.org\/10.1074\/jbc.M202238200 (2002).","journal-title":"J. Biol. Chem."},{"key":"91592_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159330","author":"D Ovejero","year":"2023","unstructured":"Ovejero, D. et al. Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI159330 (2023).","journal-title":"J. Clin. Invest."},{"issue":"21","key":"91592_CR31","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/s41388-022-02305-x","volume":"41","author":"P Odeniyide","year":"2022","unstructured":"Odeniyide, P. et al. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene 41(21), 2973\u20132983. https:\/\/doi.org\/10.1038\/s41388-022-02305-x (2022).","journal-title":"Oncogene"},{"issue":"9","key":"91592_CR32","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1158\/1535-7163.MCT-19-0958","volume":"19","author":"M Gilardi","year":"2020","unstructured":"Gilardi, M. et al. Tipifarnib as a precision therapy for HRAS-Mutant head and neck squamous cell carcinomas. Mol. Cancer Ther. 19(9), 1784\u20131796. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0958 (2020).","journal-title":"Mol. Cancer Ther."},{"issue":"6479","key":"91592_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/369411a0","volume":"369","author":"SJ Leevers","year":"1994","unstructured":"Leevers, S. J., Paterson, H. F. & Marshall, C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369(6479), 411\u2013414. https:\/\/doi.org\/10.1038\/369411a0 (1994).","journal-title":"Nature"},{"issue":"5164","key":"91592_CR34","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.7811320","volume":"264","author":"D Stokoe","year":"1994","unstructured":"Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M. & Hancock, J. F. Activation of Raf as a result of recruitment to the plasma membrane. Science 264(5164), 1463\u20131467. https:\/\/doi.org\/10.1126\/science.7811320 (1994).","journal-title":"Science"},{"issue":"19","key":"91592_CR35","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-18-3399","volume":"25","author":"A Kazi","year":"2019","unstructured":"Kazi, A. et al. Dual Farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-Driven Patient-Derived pancreatic tumors. Clin. Cancer Res. 25(19), 5984\u20135996. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3399 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"91592_CR36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/hmg\/ddm032","volume":"16","author":"M Kolanczyk","year":"2007","unstructured":"Kolanczyk, M. et al. Multiple roles for neurofibromin in skeletal development and growth. Hum. Mol. Genet. 16(8), 874\u2013886. https:\/\/doi.org\/10.1093\/hmg\/ddm032 (2007).","journal-title":"Hum. Mol. Genet."},{"issue":"12","key":"91592_CR37","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.3390\/ijms18122591","volume":"18","author":"JY Choi","year":"2017","unstructured":"Choi, J. Y. et al. Impaired osteogenesis of disease-specific induced pluripotent stem cells derived from a CFC syndrome patient. Int. J. Mol. Sci. 18(12), 2591. https:\/\/doi.org\/10.3390\/ijms18122591 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"91592_CR38","doi-asserted-by":"publisher","unstructured":"Sroga, G. E., Karim, L., Col\u00f3n, W. & Vashishth, D. Biochemical characterization of major bone-matrix proteins using nanoscale-size bone samples and proteomics methodology. Mol. Cell. Proteom. 10(9), M110.006718. https:\/\/doi.org\/10.1074\/mcp.M110.006718 (2011).","DOI":"10.1074\/mcp.M110.006718"},{"key":"91592_CR39","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.919159","author":"J Si","year":"2020","unstructured":"Si, J. et al. Osteopontin in bone metabolism and bone diseases. Med. Sci. Monit.https:\/\/doi.org\/10.12659\/MSM.919159 (2020).","journal-title":"Med. Sci. Monit."},{"issue":"2","key":"91592_CR40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.critrevonc.2013.08.013","volume":"89","author":"TE Kruger","year":"2014","unstructured":"Kruger, T. E., Miller, A. H., Godwin, A. K. & Wang, J. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit. Rev. Oncol. Hematol. 89(2), 330\u2013341. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.013 (2014).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"91592_CR41","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in Cancer. Cancer Res. 72(10), 2457\u20132467. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2612 (2012).","journal-title":"Cancer Res."},{"issue":"2","key":"91592_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.febslet.2007.12.006","volume":"582","author":"N Bokui","year":"2008","unstructured":"Bokui, N. et al. Involvement of MAPK signaling molecules and Runx2 in the NELL1-induced osteoblastic differentiation. FEBS Lett. 582(2), 365\u2013371. https:\/\/doi.org\/10.1016\/j.febslet.2007.12.006 (2008).","journal-title":"FEBS Lett."},{"issue":"3","key":"91592_CR43","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jbmr.561","volume":"27","author":"C Ge","year":"2012","unstructured":"Ge, C. et al. Interactions between extracellular signal-regulated kinase 1\/2 and P38 map kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J. Bone Miner. Res. 27(3), 538\u2013551. https:\/\/doi.org\/10.1002\/jbmr.561 (2012).","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"91592_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11005\/jbm.2022.29.1.1","volume":"29","author":"MB Greenblatt","year":"2022","unstructured":"Greenblatt, M. B., Shim, J. H., Bok, S. & Kim, J. M. The extracellular signal-regulated kinase mitogen-activated protein kinase pathway in osteoblasts. J. Bone Metab. 29(1), 1\u201315. https:\/\/doi.org\/10.11005\/jbm.2022.29.1.1 (2022).","journal-title":"J. Bone Metab."},{"issue":"39","key":"91592_CR45","doi-asserted-by":"publisher","first-page":"36181","DOI":"10.1074\/jbc.M206057200","volume":"277","author":"G Xiao","year":"2002","unstructured":"Xiao, G., Jiang, D., Gopalakrishnan, R. & Franceschi, R. T. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1\/Runx2. J. Biol. Chem. 277(39), 36181\u201336187. https:\/\/doi.org\/10.1074\/jbc.M206057200 (2002).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"91592_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1074\/jbc.M203750200","volume":"278","author":"HJ Kim","year":"2003","unstructured":"Kim, H. J. et al. The protein kinase C pathway plays a central role in the fibroblast growth Factor-stimulated expression and transactivation activity of Runx2. J. Biol. Chem. 278(1), 319\u2013326. https:\/\/doi.org\/10.1074\/jbc.M203750200 (2003).","journal-title":"J. Biol. Chem."},{"issue":"7","key":"91592_CR47","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/jcb.23094","volume":"112","author":"J Zhu","year":"2011","unstructured":"Zhu, J., Shimizu, E., Zhang, X., Partridge, N. C. & Qin, L. EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix. J. Cell. Biochem. 112(7), 1749\u20131760. https:\/\/doi.org\/10.1002\/jcb.23094 (2011).","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"91592_CR48","doi-asserted-by":"publisher","first-page":"e1187","DOI":"10.1038\/cddis.2014.101","volume":"5","author":"RL Huang","year":"2014","unstructured":"Huang, R. L., Yuan, Y., Tu, J., Zou, G. M. & Li, Q. Opposing TNF-\u03b1\/IL-1\u03b2- and BMP-2-activated MAPK signaling pathways converge on Runx2 to regulate BMP-2-induced osteoblastic differentiation. Cell Death Dis. 5(4), e1187\u2013e1187. https:\/\/doi.org\/10.1038\/cddis.2014.101 (2014).","journal-title":"Cell Death Dis."},{"issue":"23","key":"91592_CR49","doi-asserted-by":"publisher","first-page":"11263","DOI":"10.1158\/0008-5472.CAN-07-3016","volume":"67","author":"A Kilbey","year":"2007","unstructured":"Kilbey, A. et al. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res. 67(23), 11263\u201311271. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-3016 (2007).","journal-title":"Cancer Res."},{"issue":"1","key":"91592_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4161\/cam.5.1.13369","volume":"5","author":"J Forsprecher","year":"2011","unstructured":"Forsprecher, J., Wang, Z., Goldberg, H. A. & Kaartinen, M. T. Transglutaminase-mediated oligomerization promotes osteoblast adhesive properties of osteopontin and bone sialoprotein. Cell Adhes. Migr. 5(1), 65\u201372. https:\/\/doi.org\/10.4161\/cam.5.1.13369 (2011).","journal-title":"Cell Adhes. Migr."},{"issue":"6","key":"91592_CR51","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/jcp.24278","volume":"228","author":"A Neve","year":"2013","unstructured":"Neve, A., Corrado, A. & Cantatore, F. P. Osteocalcin: Skeletal and extra-skeletal effects. J. Cell. Physiol. 228(6), 1149\u20131153. https:\/\/doi.org\/10.1002\/jcp.24278 (2013).","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"91592_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/JOE-12-0143","volume":"214","author":"KA Staines","year":"2012","unstructured":"Staines, K. A., MacRae, V. E. & Farquharson, C. The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J. Endocrinol. 214(3), 241\u2013255. https:\/\/doi.org\/10.1530\/JOE-12-0143 (2012).","journal-title":"J. Endocrinol."},{"issue":"5","key":"91592_CR53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.bone.2003.11.027","volume":"34","author":"W Huang","year":"2004","unstructured":"Huang, W. et al. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 34(5), 799\u2013808. https:\/\/doi.org\/10.1016\/j.bone.2003.11.027 (2004).","journal-title":"Bone"},{"issue":"28","key":"91592_CR54","doi-asserted-by":"publisher","first-page":"19400","DOI":"10.1074\/jbc.M800005200","volume":"283","author":"N Ono","year":"2008","unstructured":"Ono, N. et al. Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J. Biol. Chem. 283(28), 19400\u201319409. https:\/\/doi.org\/10.1074\/jbc.M800005200 (2008).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"91592_CR55","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/jbmr.2079","volume":"29","author":"Q Yuan","year":"2014","unstructured":"Yuan, Q. et al. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-Deficient mice. J. Bone Miner. Res. 29(3), 693\u2013704. https:\/\/doi.org\/10.1002\/jbmr.2079 (2014).","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"91592_CR56","first-page":"2061","volume":"29","author":"S Ohshima","year":"2002","unstructured":"Ohshima, S. et al. Enhanced local production of osteopontin in rheumatoid joints. J. Rheumatol. 29(10), 2061\u20132067 (2002).","journal-title":"J. Rheumatol."},{"issue":"5","key":"91592_CR57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1023\/A:1025419708343","volume":"20","author":"G Carlinfante","year":"2003","unstructured":"Carlinfante, G. et al. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin. Exp. Metastasis 20(5), 437\u2013444. https:\/\/doi.org\/10.1023\/A:1025419708343 (2003).","journal-title":"Clin. Exp. Metastasis"},{"issue":"6","key":"91592_CR58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1203\/PDR.0b013e3181a1c607","volume":"65","author":"H Li","year":"2009","unstructured":"Li, H. et al. Ras dependent paracrine secretion of osteopontin by Nf1+\/\u2212 osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr. Res. 65(6), 613\u2013618. https:\/\/doi.org\/10.1203\/PDR.0b013e3181a1c607 (2009).","journal-title":"Pediatr. Res."},{"issue":"4","key":"91592_CR59","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.molcel.2009.08.002","volume":"35","author":"U Doehn","year":"2009","unstructured":"Doehn, U. et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile\/invasive gene program and phenotype in epithelial cells. Mol. Cell. 35(4), 511\u2013522. https:\/\/doi.org\/10.1016\/j.molcel.2009.08.002 (2009).","journal-title":"Mol. Cell."},{"issue":"1","key":"91592_CR60","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/1476-4598-9-260","volume":"9","author":"BW Robertson","year":"2010","unstructured":"Robertson, B. W., Bonsal, L. & Chellaiah, M. A. Regulation of Erk1\/2 activation by osteopontin in PC3 human prostate cancer cells. Mol. Cancer 9(1), 260. https:\/\/doi.org\/10.1186\/1476-4598-9-260 (2010).","journal-title":"Mol. Cancer"},{"key":"91592_CR61","doi-asserted-by":"publisher","unstructured":"Kusuyama, J. et al. Osteopontin inhibits osteoblast responsiveness through the down-regulation of focal adhesion kinase mediated by the induction of low\u2013molecular weight protein tyrosine phosphatase. Mol. Biol. Cell. 28(10), 1326\u20131336. https:\/\/doi.org\/10.1091\/mbc.e16-10-0716 (2017).","DOI":"10.1091\/mbc.e16-10-0716"},{"key":"91592_CR62","doi-asserted-by":"publisher","unstructured":"Chellaiah, M. A. et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol. Biol. Cell. 14(1), 173\u2013189. https:\/\/doi.org\/10.1091\/mbc.e02-06-0354 (2003).","DOI":"10.1091\/mbc.e02-06-0354"},{"key":"91592_CR63","doi-asserted-by":"publisher","unstructured":"Bergqvist, C. & Wolkenstein, P. MEK inhibitors in rasopathies. Curr. Opin. Oncol. 33(2), 110\u2013119. https:\/\/doi.org\/10.1097\/CCO.0000000000000711 (2021).","DOI":"10.1097\/CCO.0000000000000711"},{"key":"91592_CR64","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049166","author":"WE Tidyman","year":"2021","unstructured":"Tidyman, W. E., Goodwin, A. F., Maeda, Y., Klein, O. D. & Rauen, K. A. MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model. Dis. Model. Mech. https:\/\/doi.org\/10.1242\/dmm.049166 (2021).","journal-title":"Dis. Model. Mech."},{"key":"91592_CR65","doi-asserted-by":"publisher","unstructured":"Duque, G., Vidal, C. & Rivas, D. Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: Effect of alendronate, and Farnesyl and geranylgeranyl transferase inhibitors. Br. J. Pharmacol. 162(5), 1109\u20131118. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01111.x (2011).","DOI":"10.1111\/j.1476-5381.2010.01111.x"},{"key":"91592_CR66","doi-asserted-by":"publisher","unstructured":"Novelli, G. & D\u2019Apice, M. R. Protein farnesylation and disease. J. Inherit. Metab. Dis. 35(5), 917\u2013926. https:\/\/doi.org\/10.1007\/s10545-011-9445-y (2012).","DOI":"10.1007\/s10545-011-9445-y"},{"issue":"12","key":"91592_CR67","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1523\/JNEUROSCI.0449-21.2022","volume":"42","author":"H Sugiura","year":"2022","unstructured":"Sugiura, H. et al. A farnesyltransferase inhibitor restores cognitive deficits in Tsc2+\/\u2212 mice through Inhibition of Rheb1. J. Neurosci. 42(12), 2598\u20132612. https:\/\/doi.org\/10.1523\/JNEUROSCI.0449-21.2022 (2022).","journal-title":"J. Neurosci."},{"issue":"17","key":"91592_CR68","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.20.02903","volume":"39","author":"AL Ho","year":"2021","unstructured":"Ho, A. L. et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J. Clin. Oncol. 39(17), 1856\u20131864. https:\/\/doi.org\/10.1200\/JCO.20.02903 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"91592_CR69","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","volume":"78","author":"BR Untch","year":"2018","unstructured":"Untch, B. R. et al. Tipifarnib inhibits HRAS-Driven dedifferentiated thyroid cancers. Cancer Res. 78(16), 4642\u20134657. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1925 (2018).","journal-title":"Cancer Res."},{"key":"91592_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02586-x","author":"M Baranyi","year":"2024","unstructured":"Baranyi, M. et al. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. Br. J. Cancer. https:\/\/doi.org\/10.1038\/s41416-024-02586-x (2024).","journal-title":"Br. J. Cancer"},{"issue":"4","key":"91592_CR71","doi-asserted-by":"publisher","first-page":"102306","DOI":"10.1016\/j.isci.2021.102306","volume":"24","author":"TK Das","year":"2021","unstructured":"Das, T. K. et al. Drosophila rasopathy models identify disease subtype differences and biomarkers of drug efficacy. iScience 24 (4), 102306. https:\/\/doi.org\/10.1016\/j.isci.2021.102306 (2021).","journal-title":"iScience"},{"key":"91592_CR72","doi-asserted-by":"publisher","unstructured":"Ottenhoff, M. J., Krab, L. C. & Elgersma, Y. Considerations for clinical therapeutic development of statins for neurodevelopmental disorders. eNeuro 7(2). https:\/\/doi.org\/10.1523\/ENEURO.0392-19.2020 (2020).","DOI":"10.1523\/ENEURO.0392-19.2020"},{"key":"91592_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05263-y","author":"C Saint-Laurent","year":"2023","unstructured":"Saint-Laurent, C., Mazeyrie, L., Yart, A. & Edouard, T. Novel therapeutic perspectives in Noonan syndrome and rasopathies. Eur. J. Pediatr. https:\/\/doi.org\/10.1007\/s00431-023-05263-y (2023).","journal-title":"Eur. J. Pediatr."},{"key":"91592_CR74","doi-asserted-by":"publisher","unstructured":"Tajan, M. et al. Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth. Hum. Mol. Genet. 27(13), 2276\u20132289. https:\/\/doi.org\/10.1093\/hmg\/ddy133 (2018).","DOI":"10.1093\/hmg\/ddy133"},{"key":"91592_CR75","doi-asserted-by":"publisher","unstructured":"Ahmad, M. et al. Cell-based RNAi screening and high-content analysis in primary calvarian osteoblasts applied to identification of osteoblast differentiation regulators. Sci. Rep. 8(1), 14045. https:\/\/doi.org\/10.1038\/s41598-018-32364-8 (2018).","DOI":"10.1038\/s41598-018-32364-8"},{"key":"91592_CR76","doi-asserted-by":"publisher","DOI":"10.1126\/SCISIGNAL.ABM4452\/","author":"B Caratti","year":"2022","unstructured":"Caratti, B. et al. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Sci. Signal. https:\/\/doi.org\/10.1126\/SCISIGNAL.ABM4452\/ (2022).","journal-title":"Sci. Signal."}],"updated-by":[{"DOI":"10.1038\/s41598-025-98727-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91592-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:18:59Z","timestamp":1745374739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91592"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91592-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4353593\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-98727-0","URL":"https:\/\/doi.org\/10.1038\/s41598-025-98727-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6832"}}